Get a clue - analyst estimates are non-GAAP - i.e. they exclude stock based comp expense, so the $0.25 non-GAAP number actually beat by a penny. Since the stock has been knocked down about 25% since they pre-announced, I think it is due for a little rebound, especially since Q3's estimate is roughly in-line and the share buyback program has been expanded.
To clarify, the stock is down about 25% from their weak Q1 earnings release in late April (it got knocked down to ~$25 at that time) - in the Q1 earnings release they provided guidance for Q2 on billings, revenue and EPS. Earlier in July they pre-announced that billings would be a few million short of expectations, but revenue and EPS would be on target, which they just confirmed. Either way, while revenue growth will slow from the 20+% they have been delivering, there is plenty of cash ($7 per share) and future cash flow to support a $20+ share price.